ALLO-501 and ALLO-647 Phase 1 Study Overview (Allogene-Sponsored)  Initiated 1H 2019  Eligible patients with relapsed/refractory large B- cell lymphoma or follicular lymphoma and:  Failed at least two prior lines of therapy  No prior anti-CD19 therapy  Absence of pre-existing donor (product)-specific anti-HLA antibodies  Objectives:  Primary: Safety, tolerability and recommended P2 doses for ALLO-501 and ALLO-647  Secondary: Anti-tumor activity, ALLO-501 cellular Treatment: kinetics, ALLO-647 PK, immunogenicity and host • Starting cell dose:40 X 106CAR+ cells lymphocyte reconstitution  Dose-escalation of ALLO-501: 40 to 360 x 10 6 Lymphodepletion: • ALLO-647: 13 mg/d 2 3 days CAR+ cells in 3+3 design • Fludarabine: 30 mg/m /d x 3 days  Up to 24 patients • Cyclophosphamide: 300 mg/m 2/d x 3 days 15 Servier holds ex-US rights to ALLO-501
{}